Sartorius Stedim Biotech SA
DIM: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€261.00 | Lmf | Mbldcyjcy |
Wide-Moat Sartorius Stedim Delivers Strong Growth for Full-Year 2022; Raising FVE
Wide-moat Sartorius Stedim (Sartorius Ag's bioprocess subsidiary) delivered solid fourth-quarter results, and although order intakes continued to decline year over year, the company still reported revenue growth in the lower band of management’s 2022 full-year guidance, slightly below our expectations. Also, Sartorius Stedim discussed increasing its 2025 sales revenue associated with price increases due to inflation, and we plan to increase our long-term projections and fair value estimate moderately as a result.